SEC Comment Letter 0000000000-23-003568 to Inmune Bio, Inc. (INMB) (CIK 0001711754) (INMB)
Inmune Bio, Inc. (INMB) (CIK 0001711754)
Date: April 10, 2023 · CIK: 0001711754 · Accession: 0000000000-23-003568
AI Filing Summary & Sentiment
File numbers found in text: 001-38793
Letter
United States securities and exchange commission logo April 10, 2023 David Moss Chief Financial Officer Inmune Bio, Inc. 225 NE Mizner Blvd, Suite 640 Boca Raton, FL 33432 Re:Inmune Bio, Inc. Form 10-K for the fiscal year ended December 31, 2022 Filed March 2, 2023 File No. 001-38793 Dear David Moss: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
April 10, 2023
David Moss
Chief Financial Officer
Inmune Bio, Inc.
225 NE Mizner Blvd, Suite 640
Boca Raton, FL 33432
Re:Inmune Bio, Inc.
Form 10-K for the fiscal year ended December 31, 2022
Filed March 2, 2023
File No. 001-38793
Dear David Moss:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences